| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
Niflumic acid (Flunir, Donalgin, Niflactol, Niflugel, Nifluril) is a potent inhibitor of cyclooxygenase-2 (COX-2) enzyme with potential anti-inflammatory and analgesic activity. It is an approved medication used for joint and muscular pain as well as rheumatoid arthritis. Niflumic acid acts an inhibitor of COX (cyclooxygenase-2) enzyme, also a Ca2+-activated Cl- channel blocker. In experimental biology, it has been employed to inhibit chloride channels. Niflumic acid has also been reported to act on GABA-A and NMDA channels and to block T-type calcium channels.
| ln Vitro |
The combination of Ciglitazone with Niflumic acid (100 and 200 μM; 48 hours) was hazardous to A549, H460, and H1299 cells [5]. In A549, H460, and H1299 cells, nifummic acid (0-300 μM; 36 hours) in combination with ciglitazone causes apoptosis [5]. In lung cancer cells, nifummic acid (100 μM; 30 hours) plus ciglitazone activates the caspase-8/Bid/Bax pathway [5].
|
|---|---|
| ln Vivo |
In a pig asthma model, nifummic acid (30 mg/kg; breathed twice within 10 minutes) suppresses mucus granule secretory response [8].
|
| Cell Assay |
Cell Viability Assay[5]
Cell Types: A549, H460, and H1299 cells Tested Concentrations: 0 μM, 100 μM, 200 μM, 300 μM Incubation Duration: 48 h Experimental Results: demonstrated a marked synergistic decrease in cell viability with Ciglitazone. Apoptosis Analysis[5] Cell Types: A549, H460, and H1299 cells Tested Concentrations: 100 μM, 200 μM Incubation Duration: 48 h Experimental Results: demonstrated a marked synergistic increase apoptosis with Ciglitazone. Cell Viability Assay[5] Cell Types: A549, H460, and H1299 cells Tested Concentrations: 100 μM Incubation Duration: 30 h Experimental Results: demonstrated a marked synergistic increase of protein level of caspase-8, Bid, and Bax with Ciglitazone. |
| Animal Protocol |
Animal/Disease Models: Pig with asthma [8]
Doses: 30 mg/kg Route of Administration: Inhalation Experimental Results: demonstrated Dramatically inhibiting the decrease in mucus area. |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Well absorbed following oral administration. Metabolism / Metabolites Hepatic. Biological Half-Life 2.5 hours |
| Toxicity/Toxicokinetics |
Protein Binding
90% bound to plasma proteins. |
| References |
|
| Additional Infomation |
Niflumic acid is an aromatic carboxylic acid and a member of pyridines.
Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. Drug Indication Used in the treatment of rheumatoid arthritis. Mechanism of Action Niflumic acid is able to inhibit both phospholipase A2 as well as COX-2, thereby acting as an antiinflamatory and pain reduction agent. Pharmacodynamics Niflumic acid, a nonsteroidal anti-inflammatory fenamate, is a Ca2+-activated Cl- channel blocker. |
| Molecular Formula |
C13H9F3N2O2
|
|
|---|---|---|
| Molecular Weight |
282.22
|
|
| Exact Mass |
282.061
|
|
| CAS # |
4394-00-7
|
|
| Related CAS # |
Niflumic Acid-d5;1794811-58-7;Niflumic acid-13C6;1325559-33-8
|
|
| PubChem CID |
4488
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| Density |
1.4±0.1 g/cm3
|
|
| Boiling Point |
378.0±42.0 °C at 760 mmHg
|
|
| Melting Point |
203-204ºC
|
|
| Flash Point |
182.4±27.9 °C
|
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
|
| Index of Refraction |
1.589
|
|
| LogP |
4.94
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
7
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
20
|
|
| Complexity |
349
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
JZFPYUNJRRFVQU-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)
|
|
| Chemical Name |
2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5433 mL | 17.7167 mL | 35.4333 mL | |
| 5 mM | 0.7087 mL | 3.5433 mL | 7.0867 mL | |
| 10 mM | 0.3543 mL | 1.7717 mL | 3.5433 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05761015 | Not yet recruiting | Drug: therapeutic program including intermittent drug intake and multimodal rehabilitation program |
Osteoarthritis, Knee Osteoarthritis, Hip Chronic Pain |
University Hospital, Clermont-Ferrand | December 1, 2023 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA